Real-world molecular profiles, treatment and outcomes by HER2 IHC score in patients with advanced endometrial cancer in the United States of America
IGCS 2026
John Nakayama, Nehemiah Kebede, Zulikhat Segunmaru, Aaron Springford, Sonia Iyer, Yaozhu J. Chen, Ebony Hoskins
Introduction
HER2 overexpression is an important prognostic and predictive biomarker in endometrial cancer (EC). HER2-targeted therapies have shown efficacy in patients with HER2-expressing advanced EC (aEC), but testing rates remain low. To examine the clinical relevance of HER2 expression, we describe a large real-world population with aEC by immunohistochemistry (IHC) score.
Methods
This retrospective, observational cohort study used data from the Tempus AI multi-modal real-world oncology database to identify US adults diagnosed with aEC (stage III/IV, recurrent and newly diagnosed) who were mismatch repair (MMR) tested and initiated first-line treatment between January 1, 2018 to May 31, 2024. Patient characteristics, treatment patterns, real-world progression-free survival (rwPFS) and overall survival (rwOS) are reported for the subgroup with documented HER2 IHC results (N=300, 26.8%), representing a large real-world HER2-characterized aEC cohort.
Results
Serous adenocarcinoma was the most common histology across all HER2 IHC scores. The prevalence of p53-abnormality increased with higher HER2 IHC scores. No POLE-mutated tumors were identified among those tested (Table 1). Chemotherapy alone was the most common first-line treatment in IHC 0, 1+ and 2+ subgroups. For IHC 3+, approximately 75% received HER2-targeted therapy plus chemotherapy (without additional agents), and median rwPFS from start of first-line was longer, and 12-month rwOS higher, than in IHC 0–2+ (Table 2).
Conclusion/Implications
Treatment patterns and outcomes in aEC varied by HER2 IHC subgroup score and may reflect a benefit associated with HER2-targeted therapies. These findings reinforce the clinical relevance of routine HER2 testing and support further evaluation of HER2-directed strategies in earlier lines of therapy.
Related publications